This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ACTG 193A was a randomized, double-blind, four-arm phase 2 treatment study in advanced HIV disease. The registry title describes comparisons among combination nucleoside, alternating nucleoside, and triple-drug therapy in patients with CD4 ≤50/mm3.
| Feature | ACTG 193A |
|---|---|
| Study title | A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 ≤ 50/mm3) |
| Acronym | ACTG 193A |
| ClinicalTrials.gov identifier | NCT00000781 |
| Phase | Phase 2 |
| Status | Completed |
| Condition | HIV Infections |
| Primary purpose | Treatment |
| Masking | Double |
| Enrollment | 1292 |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
2. Clinical Question
The registry describes a treatment question in advanced HIV disease: how different nucleoside-based treatment strategies, including combination, alternating, and triple-drug approaches, compare within a randomized, double-blind, four-arm phase 2 study.
Population
Patients with advanced HIV disease, defined in the study title by CD4 ≤50/mm3.
Interventions
The registry lists nevirapine, zidovudine, zalcitabine, and didanosine as study interventions.
Comparator structure
The study title describes a four-arm comparison involving combination nucleoside, alternating nucleoside, and triple-drug therapy.
Primary question
How do the randomized treatment strategies compare in the treatment of advanced HIV disease?
3. Trial Design
The study title establishes three important design features: randomization, double blinding, and four treatment arms. The study was classified as phase 2 and had a primary purpose of treatment.
Four-arm structure
A four-arm randomized trial creates a different statistical problem from a conventional two-group trial. There are potentially multiple treatment comparisons, and the interpretation depends on which comparisons were prespecified as scientifically important. The registry title identifies the broad treatment strategies but does not provide the arm-by-arm treatment assignment structure in the record represented here.
4. Interventions
| Intervention | Type |
|---|---|
| Nevirapine | Drug |
| Zidovudine | Drug |
| Zalcitabine | Drug |
| Didanosine | Drug |
The registry lists four drug interventions: nevirapine, zidovudine, zalcitabine, and didanosine. The study title describes the treatment strategies as combination nucleoside, alternating nucleoside, and triple-drug therapy. The record does not provide enough arm-level detail here to assign a particular drug combination to each of the four randomized arms.
5. Endpoints
| Endpoint category | Registry information |
|---|---|
| Registered primary endpoints | None listed in the ClinicalTrials.gov record. |
| Endpoint definitions | No registered primary endpoint definition is reported in the record. |
| Time frames | No registered primary endpoint time frames are reported in the record. |
This distinction is important statistically. A randomized clinical trial can have a detailed treatment question without the registry record supplying a formal endpoint definition. Without a specified endpoint, the statistical analysis cannot be tied to a particular event definition, measurement scale, assessment schedule, or analysis time point.
6. Statistical Methodology
Because the registry record does not list registered primary endpoints or posted statistical analyses, the appropriate statistical framework must be described according to the type of question created by the design rather than as a report of an analysis actually posted in the registry.
Randomized comparison
Randomization provides the principal framework for comparing the four treatment strategies. If treatment assignment is randomized and the analysis follows the randomized groups appropriately, differences between groups can be interpreted in relation to the assigned treatment rather than simply as associations between treatment received and outcome.
Four-arm inference
With four randomized groups, there are multiple possible pairwise comparisons as well as the possibility of an overall test across all treatment groups. The choice among these approaches should be driven by the prespecified scientific question. A four-group analysis should not automatically be reduced to a series of unadjusted pairwise tests.
For a quantitative endpoint, an overall null hypothesis can ask whether the treatment groups have the same underlying parameter. The exact parameter and statistical test depend on the endpoint type.
Continuous outcomes
If a primary outcome were continuous, a comparison of four randomized groups could use an analysis of variance or a regression model, with appropriate adjustments for prespecified covariates where justified. Pairwise treatment contrasts would then require explicit multiplicity consideration when several comparisons are interpreted together.
Binary outcomes
If an outcome were binary, the analysis could compare response proportions across treatment groups using a model or test appropriate to the design. Effect measures such as risk differences, risk ratios, or odds ratios would provide different interpretations and should be selected according to the scientific endpoint.
Time-to-event outcomes
If the endpoint were time to an event, Kaplan-Meier methods and a Cox proportional-hazards model could be appropriate, depending on the endpoint definition and analysis plan. The hazard ratio would describe a relative event-rate measure rather than a difference in survival probabilities at a particular time.
Repeated measurements
If outcomes such as laboratory or immunologic measurements were collected repeatedly over follow-up, a longitudinal model could account for within-patient correlation. The appropriate model would depend on the measurement scale, visit structure, missingness, and prespecified estimand.
7. Planned Analysis
The ClinicalTrials.gov record identifies a randomized, double-blind, four-arm treatment study but does not list registered primary endpoints. No posted statistical analyses are present in the record.
What would normally be defined first?
A statistical analysis would begin with an explicit primary endpoint, including its measurement, event definition if applicable, assessment window, and analysis population.
How would four arms be handled?
The analysis would identify the prespecified treatment contrasts or an overall four-group hypothesis and then control interpretation appropriately when multiple comparisons are made.
How would uncertainty be reported?
Effect estimates should ordinarily be accompanied by confidence intervals or another prespecified measure of uncertainty appropriate to the endpoint.
What about missing observations?
The analysis plan would normally specify how missing outcome measurements, withdrawals, and incomplete follow-up are handled for the primary endpoint.
For a four-arm randomized treatment study, the key statistical distinction is between describing all four groups and conducting a formally controlled set of treatment comparisons. A complete analysis plan would specify which comparison answers the principal clinical question before examining the observed outcomes.
8. Statistical Methods Explained
Why does a four-arm trial require more than a simple two-group comparison?
Four randomized groups create several possible treatment contrasts. If each group is compared with every other group using an unadjusted significance test, the overall chance of obtaining at least one apparently positive result can increase. A prespecified comparison strategy therefore matters.
What does randomization contribute to the analysis?
Randomization establishes the treatment assignment mechanism before outcomes are observed. In a properly conducted randomized comparison, baseline differences arise from chance rather than from deliberate selection of treatment for particular patients. This is the foundation for causal interpretation of differences between randomized groups.
Why is double blinding statistically important?
Blinding can reduce the influence of treatment knowledge on patient management, outcome assessment, reporting, and decisions made during follow-up. Its value depends on what is being measured and on whether the intervention can successfully remain masked.
Why is an overall four-group test different from pairwise testing?
An overall test asks whether there is evidence that the groups differ somewhere across the four-group comparison. Pairwise tests answer more specific questions. A significant overall test does not identify which particular groups differ, while a collection of unadjusted pairwise tests can create a multiplicity problem.
Why must the endpoint be defined before choosing the statistical test?
The appropriate statistical method depends on the outcome's structure. A binary endpoint, continuous measurement, count, repeated measurement, and time-to-event endpoint each require different assumptions and effect measures. Without a defined endpoint, there is no single statistically justified primary test to report.
What would a hazard ratio mean if the primary endpoint were time to event?
A hazard ratio below 1 would indicate a lower estimated instantaneous event rate in one randomized group relative to another under a proportional-hazards model. It would not directly represent the probability of an event, the absolute risk difference, or the percentage of patients benefiting.
9. Multiplicity in a Four-Arm Trial
Multiplicity is especially important when a study contains four randomized treatment groups. There are six possible unordered pairwise comparisons among four groups. Not every trial intends to test all six comparisons, and the registry record does not identify a prespecified comparison hierarchy.
The combinatorial count illustrates why the analysis plan must distinguish the primary comparison from secondary or exploratory comparisons.
Possible approaches to multiplicity include hierarchical testing, adjustment of significance levels, closed-testing procedures, or prespecified contrasts. The appropriate method depends on the hypotheses the trial was designed to address.
10. Analysis Populations
The registry record does not specify analysis populations for efficacy or safety. In randomized trials, however, the distinction between randomized, treated, and evaluable populations can materially affect interpretation.
| Population concept | Statistical role |
|---|---|
| Intention-to-treat | Analyzes patients according to randomized treatment assignment and preserves the principal benefit of randomization. |
| Per-protocol | Can focus on patients who adhered sufficiently to protocol requirements, but may be more vulnerable to post-randomization selection. |
| Safety / as-treated | Typically focuses on patients who actually received treatment and is useful for exposure-related safety summaries. |
| Evaluable population | May be defined for a particular endpoint, but exclusion from the randomized population can affect comparability between treatment groups. |
The choice of analysis population should be determined by the endpoint and estimand rather than selected after observing which population produces a preferred result.
11. Missing Data and Follow-Up
The ClinicalTrials.gov record does not specify a missing-data or imputation strategy. This is an important component of any formal analysis because incomplete follow-up can affect both the estimate and its uncertainty.
For a continuous endpoint, possible approaches include model-based analyses or prespecified imputation methods. For a binary endpoint, missing outcomes may require an explicit handling rule or an appropriate model. For time-to-event endpoints, censoring rules are central to the analysis.
Missing outcome
The analysis should distinguish a missing measurement from a confirmed absence of the event.
Censoring
For time-to-event analysis, censoring determines how much follow-up information remains available from patients who do not experience the event during observation.
12. Stratification and Covariate Adjustment
The registry record does not identify randomization strata or prespecified covariates for the primary analysis. Therefore, no specific stratified statistical model can be attributed to ACTG 193A from this record.
In a randomized four-arm trial, baseline covariate adjustment can improve precision when the covariates are prespecified and appropriately modeled. It should not be used to compensate for post-randomization differences or to selectively emphasize favorable comparisons.
13. Safety Analysis
The registry record identifies the study as a treatment trial and lists four drug interventions, but it does not provide serious adverse-event counts by treatment arm.
| Safety element | Registry information |
|---|---|
| Serious adverse events by arm | Not reported in the ClinicalTrials.gov record. |
| Adverse-event rates | Not reported in the ClinicalTrials.gov record. |
| Safety analysis population | Not specified in the ClinicalTrials.gov record. |
| Comparative safety estimate | Not reported in the ClinicalTrials.gov record. |
For a randomized four-arm treatment study, safety analysis would ordinarily summarize the number and proportion of participants experiencing adverse events in each arm, with serious adverse events considered separately. Exposure duration and treatment discontinuation can also matter when interpreting event frequencies.
14. What the Enrollment Number Means Statistically
Total enrollment
Patients enrolled in ACTG 193A according to the ClinicalTrials.gov record.
The enrollment count describes the size of the study population recorded by the registry. It does not, by itself, establish statistical power for any particular endpoint. Power depends on the endpoint, treatment contrast, event rate or outcome variability, significance level, allocation proportions, and other design assumptions.
In a four-arm trial, total enrollment also needs to be considered together with the allocation of patients across the four groups. The registry record represented here does not provide the sample size assigned to each arm.
15. Phase 2 Statistical Context
ACTG 193A is identified as a phase 2 study. Phase 2 trials can be designed to investigate treatment activity, compare candidate regimens, characterize safety, or generate evidence for later development. The statistical interpretation depends on the trial's prespecified objective rather than on the phase label alone.
The completed status indicates that the study has been completed in the registry. It does not itself provide evidence about treatment efficacy, statistical significance, or clinical benefit.
16. Statistical Interpretation of the Four-Arm Structure
The randomized design is the central feature supporting comparative inference. Treatment assignment is determined independently of the eventual outcome, allowing observed differences to be interpreted within the framework created by the randomization.
Four arms create multiple potential treatment contrasts. The more comparisons that are treated as confirmatory, the more important prespecified multiplicity control becomes.
No numerical treatment-effect estimate is reported in the registry record. Consequently, the statistical interpretation is limited to the design and the principles that would govern analysis rather than an observed efficacy estimate.
No confidence intervals or other numerical measures of treatment-effect uncertainty are reported in the registry record. In a formal analysis, uncertainty should accompany each clinically relevant effect estimate.
17. Limitations
- No registered primary endpoints: the ClinicalTrials.gov record does not list primary endpoint definitions or time frames.
- No posted statistical analyses: the registry record contains no posted statistical analysis results.
- No arm-level sample sizes: total enrollment is 1292, but the registry record does not provide the number assigned to each of the four treatment arms.
- Limited regimen detail: the registry lists nevirapine, zidovudine, zalcitabine, and didanosine, while the study title describes combination nucleoside, alternating nucleoside, and triple-drug therapy; the arm-specific combinations are not provided in the record represented here.
- No numerical efficacy estimates: the record does not report treatment-effect estimates, confidence intervals, or p-values.
- No safety counts by arm: serious adverse-event counts and other comparative safety results are not reported in the registry record.
- No analysis-population definitions: the registry record does not specify ITT, per-protocol, safety, or endpoint-specific analysis populations.
- No missing-data strategy: the registry record does not identify an imputation, censoring, or missing-data approach.
18. Why This Trial Matters Statistically
ACTG 193A is a useful statistical teaching case because its design combines randomization, four treatment arms, double blinding, and multiple nucleoside-based treatment strategies in a phase 2 setting.
| Concept | How it appears in ACTG 193A |
|---|---|
| Randomization | The study title identifies the study as randomized. |
| Blinding | The registry identifies the masking as double. |
| Multiple treatment arms | The study is explicitly described as a four-arm study. |
| Multiplicity | Four randomized groups create multiple possible treatment contrasts. |
| Endpoint specification | No registered primary endpoints are listed in the ClinicalTrials.gov record. |
| Analysis populations | The registry record does not specify efficacy or safety analysis populations. |
| Missing data | No missing-data or imputation strategy is reported in the record. |
| Safety analysis | Serious adverse events by treatment arm are not reported in the record. |
| Statistical inference | No treatment-effect estimates, confidence intervals, or p-values are posted in the record. |
The statistical lesson is that trial design and statistical reporting are complementary. Randomization establishes the comparative framework, but a complete statistical interpretation also requires a clearly defined endpoint, analysis population, treatment contrast, uncertainty measure, and prespecified inferential strategy.
19. Sources
- ClinicalTrials.gov: ACTG 193A, NCT00000781.
Continue through the Clinical Biostats clinical trial library
Clinical trial analysis is most useful when study design, endpoints, estimands, treatment contrasts, uncertainty, and statistical assumptions are considered together.
20. Record Summary
ACTG 193A was a completed, randomized, double-blind, four-arm phase 2 treatment study enrolling 1292 participants with advanced HIV disease defined in the study title by CD4 ≤50/mm3. The registry lists nevirapine, zidovudine, zalcitabine, and didanosine as interventions and describes the study as a comparison of combination nucleoside, alternating nucleoside, and triple-drug therapy. The ClinicalTrials.gov record does not list registered primary endpoints or post statistical analyses, so the available statistical evidence is limited to the documented study design and the general inferential framework appropriate for a randomized four-arm treatment trial.